- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01845103
The PEARL 8.0 Post-Approval Study
Post-Approval Study of the PEARL 8.0 Handpiece for Transmyocardial Revascularization (TMR) With the Cardiogenesis Holmium:YAG Laser System
Study Overview
Status
Conditions
Detailed Description
This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery System. The PEARL 8.0 Handpiece allows the TMR laser energy to be directed at the heart through a small port up to 8 mm in size. The purpose of this study is to demonstrate that the 30 day mortality rate among patients who receive this device is less than the historical rate plus a non-inferiority margin. In a recent study of 34 patients treated with the PEARL 8.0 device, 3 (8.8%) experienced 30 day mortality. Among 132 patients in the original PMA trial treated with the SoloGrip III Handpiece, a similar device delivering identical energy, the 30 day mortality rate was 5.3% (7/132). In the Post-Approval Study of the SoloGrip III Handpiece, 2/72 prospectively enrolled patients died within the first 30 days. Therefore, the weighted average of the Pre-market and post-market studies has been calculated (4.4%) and will serve as the historical rate.
This trial will be monitored for success and futility according to a Bayesian adaptive design. Based on prior history, we assume patients will be accrued at the rate of approximately 1 patient per month and therefore, 30 day mortality will be known for all currently enrolled patients at the time each new patient is enrolled.
The success stopping boundaries for this study are 0/10 and 1/22. Thus, if no deaths are observed among the first 10 patients, the study will stop for success. If 1 death is observed among the first 10 patients, the study will continue to enroll. If among the first 22 patients, only 1 death is observed (there are no additional deaths), the study will stop for success. At any time, if 2 or more deaths are observed, the study will stop for futility.
A secondary objective is to assess the effect of channel number on the 30 day mortality rate to justify the labeling claims that the risk for early post-operative (30 day) mortality is associated with an increased number of channels, and not the function of the operation or device.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95816
- Sutter Institute for Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Class IV angina (according to Canadian Cardiovascular Society Angina Scale)
- Ejection Fraction > 30%
- Patients with regions of myocardium in the distal two-thirds of the left ventricle with reversible ischemia and who are not eligible for direct coronary revascularization (e.g., CABG or PTCA).
- Patients amenable to thoracoscopic TMR.
Exclusion Criteria:
- Age less than18-years
- Pregnant or nursing mothers
- Unable to undergo a surgical procedure or general anesthesia
- Hepatic disease, renal failure, cancer or major infection
- Severely unstable angina (un-weanable from intravenous anti-anginals for 48- hours)
- Patients with mechanical/prosthetic heart valves
- Myocardial ischemia limited to the right ventricular wall
- Q-Wave myocardial infarction within three (3) weeks prior to the procedure
- Non Q-Wave myocardial infarction within two (2) weeks prior to the procedure
- Requires anticoagulation medications or has other hemorrhagic propensity
- Severe arrhythmia within one week prior to the procedure
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: 30 day
|
30 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Coronary and Cerebrovascular Events (MACCE)
Time Frame: 30 day
|
MACCE includes: Cardiac related death, CVA, Myocardial Infarction, Serious arrhythmia, CHF |
30 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PLT1101.003-M
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Class IV Angina
-
Cardiogenesis Corporation, a wholly-owned subsidiary...CompletedClass IV AnginaUnited States
-
CryoLife, Inc.CompletedClass IV AnginaUnited States
-
Wuerzburg University HospitalCharite University, Berlin, Germany; Goethe University; RWTH Aachen University; Technical University of Munich and other collaboratorsRecruitingSurgery | ASA Class III/IV Patients | Clinical Decision Support SystemsGermany
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
Comunicare Solutions SAKU Leuven; Jessa Hospital; Cliniques universitaires Saint-Luc- Université Catholique... and other collaboratorsRecruitingHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVBelgium
-
Elpen Pharmaceutical Co. Inc.WithdrawnHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV
-
John ParissisCompletedHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV | Heart Failure NYHA Class IGreece
-
University of Turin, ItalyCompletedHeart Failure NYHA Class III | Heart Failure NYHA Class IVItaly
-
University of LouisvilleThoratec CorporationUnknownHeart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
NuPulseCVUnknownHeart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States